Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. (Q51372246)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Padma Sathyanarayana

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Medhavi Jogi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ramkumar Krishnamurthy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Susan L Samson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Mandeep Bajaj

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

9 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

2310-2315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Liver fat in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Cell signalling of the GLP-1 action in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

inferred from DOI database lookup

7 January 2021

based on heuristic

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.152

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2011.152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660077%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference